Clinical trial
Octreotide With or Without Prednisone in Treating Patients With Metastatic or…
NCT00003283 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00003283 |
|---|---|
| Title | Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma |
| Official title | Phase II Study of Octreotide Treatment of Advanced, Recurrent Thymoma |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Thymoma and Thymic Carcinoma |
| Intervention type | Drug |
| Interventions | octreotide acetate, prednisone |
| Enrollment | 38 |
| Start date | Oct 13, 1998 |
| Primary completion | Sep 1, 2003 |
| First posted | Apr 14, 2004 |
| Last update posted | Jun 15, 2023 |
| Countries | South Africa, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: